CAJ | 학술논문

目的应用免疫组化方法检测叉头/翼状螺旋转录因子P1(FOXP1)和细胞周期蛋白(Cyclin)E在免疫功能正常的原发性中枢神经系统淋巴瘤(PCNSL)患者中的表达情况并评价其预后判断价值.方法回顾性分析2002年至2007年71例初发PCNSL患者的临床资料.采用免疫组化染色法(HRP-EnVision TM)观察患者肿瘤组织标本FOXP1和Cyclin E的表达情况,并结合临床资料对两者在PCNSL患者预后中的意义进行分析.结果检测的51例初发PCNSL患者中35例(68.63%)肿瘤细胞FOXP1表达阳性; 检测的50例初发PCNSL患者中29例(58.00%)肿瘤细胞Cyclin E表达阳性.FOXP1阳性表达者的生存期较阴性者缩短,FOXP1阳性表达者2年总体生存(OS)率为23.33%,FOXP1阴性表达者的2年OS率为73.56%(P=0.0015).Cyclin E阳性表达者的生存期较阴性表达者缩短.Cyclin E阳性表达者2年OS率为17.56%,阴性表达者的2年OS率为69.76%(P=0.0017).多因素分析显示Cyclin E阳性表达为独立的预后影响因素(P=0.048).FOXP1阳性可能为PCNSL重要的预后不良因素(P=0.065).结论 Cyclin E阳性可作为PCNSL预后评估的影响因素.FOXP1阳性可作为PCNSL预后不良的参考因素.
목적 응용면역조화방법검측차두/익상라선전록인자P1(FOXP1)화세포주기단백(Cyclin)E재면역공능정상적원발성중추신경계통림파류(PCNSL)환자중적표체정황병평개기예후판단개치.방법 회고성분석2002년지2007년71례초발PCNSL환자적림상자료.채용면역조화염색법(HRP-EnVision TM)관찰환자종류조직표본FOXP1화Cyclin E적표체정황,병결합림상자료대량자재PCNSL환자예후중적의의진행분석.결과 검측적51례초발PCNSL환자중35례(68.63%)종류세포FOXP1표체양성; 검측적50례초발PCNSL환자중29례(58.00%)종류세포Cyclin E표체양성.FOXP1양성표체자적생존기교음성자축단,FOXP1양성표체자2년총체생존(OS)솔위23.33%,FOXP1음성표체자적2년OS솔위73.56%(P=0.0015).Cyclin E양성표체자적생존기교음성표체자축단.Cyclin E양성표체자2년OS솔위17.56%,음성표체자적2년OS솔위69.76%(P=0.0017).다인소분석현시Cyclin E양성표체위독립적예후영향인소(P=0.048).FOXP1양성가능위PCNSL중요적예후불량인소(P=0.065).결론 Cyclin E양성가작위PCNSL예후평고적영향인소.FOXP1양성가작위PCNSL예후불량적삼고인소.
Objective To evaluate the value of FOXP1 and Cyclin E gene in primary central nervous system lymphoma(PCNSL) of immunocomptent patients on prognostic significance. Methods Clinical data of 71 patients with newly diagnosed PCNSL from 2002 to 2007 was analyzed retrospectively. Immunohistochemistry method (HRP-EnVisionTM)was performed to observe the expression of FOXP1 and Cyclin E gene in tumor tissue samples. The survival was analyzed by Kaplan-Meier survival curve, survival factors analysis by the Log-rank test and COX proportional hazards regression model. Results FOXP1 positive was observed in 35 of 51 patients (68.63%)and Cyclin E staining was present in 29 of 50 cases(58.00%). FOXP1+ patients had a shorter overall survival(OS) than FOXP1- ones. 2-year OS rate in FOXP1+ and FOXP1- patients were 23.33% and 73.56%, respectively(P=0.0015). Cyclin E+ patients had a shorter overall survival(OS) than cyclinE- ones. 2-year OS rate in Cyclin E+ and Cyclin E- patients were 17.56% and 69.76%, respectively(P=0.0017). Multivariate analysis showed that Cyclin E expression was an independent prognostic factor for shorter OS(P=0.048). FOXP1 expression might be an important prognostic factor for shorter OS(P=0.065). Conclusion Cyclin E expression is an independent prognostic factor and FOXP1 expression is a possible prognostic factor for poor clinical outcome in patients with PCNSL.